Effects of physical activity and exercise on glycaemic control in cystic fibrosis

Not Applicable

Completed

• Conditions: Cystic fibrosis; Cystic Fibrosis related diabetes; Respiratory - Other respiratory disorders / diseases; Metabolic and Endocrine - Diabetes; Human Genetics and Inherited Disorders - Cystic fibrosis

• Registration Number: ACTRN12622000385741
• Lead Sponsor: Royal Prince Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-04
• Study Completion: 2024-04-11
• Last Update Posted: 10 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

a.RPAH CF clinic patients, aged 17 years and over, who are clinically stable.
b. CF Patients with Cystic fibrosis related diabetes( CFRD) (n=15), impaired fasting glucose tolerance (n=15) and those with normal glycaemic control (n=15), according to their most recent oral glucose tolerance test (within 3 years, where applicable).
c. Clinically-stable at time of data collection, as assessed by the patient’s treating respiratory physician, including no non-routine antibiotics in the previous 14 days.

d. Provides informed consent. e. Eligible for Elexacaftor/Tezacaftor/ Ivacaftor (TrikaftaTM) · Healthy control participants:
. Healthy clinically stable participants, aged 17 years and over.
No history of cardiovascular, neuromuscular, endocrine, respiratory disease

Exclusion Criteria

a. Unable to perform moderate intensity exercise or use continuous glucose monitoring device. b. Colonisation with Tier 3 organisms (Burkholderia cepacia, non-tuberculous mycobacteria) c. Previous lung transplant. d. Pregnant or lactating females. e. Known hypoglycaemia unawareness f. Mobile phone not compatible with the continuous glucose monitoring devic

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood glucose control monitored with continuous flash glucometer related to exercise measured withactiPal[ Continous monitoring of blood glucose for 10 days]

Secondary Outcome Measures

Name	Time	Method
Blood glucose control monitored with continuous flash glucometer related to exercise measured with actiPal following initiation of Trikafta[ 4 weeks after initial observation]; Body composition via Dual Energy X-ray Absorptiometry before and after commencement of Trikafta.[ Before and within 1 year after commencement of Trikafta.]